SEARCH

SEARCH BY CITATION

References

  • 1
    Gershlick AH. Antiplatelet therapy. Hospital Medicine 2000; 61: 1523.
  • 2
    Easton DJ. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Seminars in Thrombosis and Hemostasis 1999; 25: 7782.
  • 3
    Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arteriosclerosis Thrombosis Basic Biology 1999; 19: 200711.
  • 4
    Gauchet C. ADP receptors of platelets and their inhibition. Thrombosis and Haemostasis 2001; 86: 22232.
  • 5
    Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombocytopenic purpura due to ticlopidine following coronary stenting. Journal of the American Medical Association 1999; 281: 80610.
  • 6
    Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading regimens: kinetic profile of pharmacodynamic response in healthy subjects. Seminars in Thrombosis and Hemotasis 1999: 25 (Suppl. 2): 1519.
  • 7
    Thebault JJ, Kieffer G, Lowe WS, Cariou R. Repeated dose pharmacodynamics of clopidogrel in healthy subjects. Seminars in Thrombosis and Hemotasis 1999; 25 (Suppl. 2): 914.
  • 8
    Herbert J-M, Savi P, Maffrand J-P. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. European Heart Journal 1999; Suppl A: A3140.
  • 9
    Jarvis B, Simpson K. Clopidogrel. A review of its use in the prevention of atherothrombosis. Drugs 2000; 60: 34777.
  • 10
    Weber AA, Brasun M, Hohfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology 2001; 52: 3336.
  • 11
    McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability is unaffected by food or antacids. Journal of Clinical Pharmacology 1996; 36: 856.
  • 12
    Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 54:74550.
  • 13
    Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Seminars in Thrombosis and Hemostasis 1999; 25: 258.
  • 14
    Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thrombosis and Haemostasis 1994; 72: 31317.
  • 15
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 132939.
  • 16
    Hankey GJ. Current oral antiplatelet agents to prevent atherothrombosis. Cerebrovascular Disease 2001; 11 (Suppl. 2): 1117.
  • 17
    Bennet CL, Connors JM, Carwiole JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New England Journal of Medicine 2000; 342: 17737.
  • 18
    Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients; Ticlopidine Aspirin Stroke Study. New England Journal of Medicine 1989; 321: 5017.
  • 19
    Fisher AA, Le Couteur DG. Intracerebral haemorrhage following possible interaction between celecoxib and clopidogrel. Annals of Pharmacotherapy 2001; 35: 15679.
  • 20
    Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clinical Pharmacology and Therapeutics 1997; 62: 5727.
  • 21
    Colli A, Buccino G, Cocciollo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine–theophylline interaction. Clinical Pharmacology and Therapeutics 1987; 41: 35862.
  • 22
    Brown RI, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Canadian Journal of Cardiology 1997; 13: 5727.
  • 23
    Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 6249.
  • 24
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001; 345: 494502.
  • 25
    Mehta SR, Yusof S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 52733.
  • 26
    Moore SA, Steinhubl SR. Clopidogrel and coronary stenting: what is the next question? Journal of Thrombosis and Thrombolysis 2000; 10: 1216.
  • 27
    Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. American Journal of Medicine 1999; 107: 56872.
  • 28
    Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovascular Disease 2002; 13 (Suppl. 1): 226.
  • 29
    Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. New England Journal of Medicine 1998; 339: 166571.
  • 30
    Bertrand M, Legrand B, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597603.
  • 31
    Urban P, Macaya C, Rupprecht H, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998; 98: 212632.
  • 32
    Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New England Journal of Medicine 1996; 334: 10849.
  • 33
    Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: results from STIMS, the Swedish Ticlopidine Multicentre Study. Journal of Internal Medicine 1990; 227: 3018.
  • 34
    Berqvist D, Almgren B, Dickinson JP. Reduction of requirement of leg vascular surgery during long term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (StIMS) European Journal of Vascular and Endovascular Surgery 1995; 10: 6975.
  • 35
    Becquemin JP. Effect of ticlopidine on the long term patency of saphenous vein grafts in the legs. New England Journal Medicine 1999; 337: 172631.
  • 36
    Thiagarajan P, Wu KK. Mechanisms of antithrombotic drugs. Advances in Pharmacology 1999; 46: 297324.
  • 37
    Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994; 308: 81106.
  • 38
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high-risk patients. British Medical Journal 2002; 324: 7186.
  • 39
    Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New England Journal of Medicine 2000; 342: 17737.
  • 40
    Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Seminars in Thrombosis Hemostasis 1998; 24: 195202.
  • 41
    Mukherjee D, Moliterno DJ. Monitoring antiplatelet therapy. Clinical Pharmacokinetics 2000; 39: 4458.
  • 42
    Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. American Heart Journal 1998; 135: S1708.
  • 43
    Keser AC. Antiplatelet agents and spinal anesthesia. Anesthetist 2000; 49: 2345.
  • 44
    Berglund U, Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. Journal of Invasive Cardiology 2002; 14: 2436.
  • 45
    Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. British Journal of Surgery 2001; 88: 787800.
  • 46
    Kovesi T, Royston D. Is there a problem with platelet active drugs? British Journal of Anaesthesia 2002; 88: 159163.
  • 47
    Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Critical Care Medicine 2001; 29: 22715.
  • 48
    D'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surgery Forum 2001; 4: 3548.
  • 49
    Herbert JM, Bernat A, Maffrand JP. Aprotinin reduces clopidogrel induced prolongation of the bleeding time in the rat. Thrombosis Research 1993; 71: 43341.
  • 50
    Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Cochrane Review) The Cochrane Library, Issue 2. Oxford: Update Software, 2002.